Literature DB >> 12072063

Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model.

M Erdogan1, J R Wright, V C McAlister.   

Abstract

BACKGROUND: Systemic but not topical tacrolimus (TAC) is effective against psoriasis. Mechanical methods that enhance skin penetration by TAC increase its topical antipsoriatic effect. Liposomal delivery of TAC would increase its penetration of skin, allow for slow release and diminish its toxicity.
OBJECTIVES: To test a liposomal TAC (LTAC) formulation in a murine model.
METHODS: Drug penetration was assessed using radiolabelled LTAC, and the effect of TAC and LTAC on Balb/c skin graft survival and on ovalbumin-induced delayed-type hypersensitivity reactions was tested in C57BL/6 mice.
RESULTS: Radiotracer studies showed that topical application of LTAC achieved nine times the concentration of TAC at a target site than did systemic administration of TAC. Combination of systemic and topical LTAC significantly increased mean +/- SD skin graft survival (14.8 +/- 1.5 days) compared with systemic TAC (8.0 +/- 0.7 days) and control mice (8.4 +/- 1.2 days). LTAC was more effective systemically than TAC in the prevention of delayed-type hypersensitivity reactions. Topical LTAC also prevented this response.
CONCLUSIONS: Topical LTAC was effective in this model of immune-mediated skin disease. Because LTAC achieves higher skin concentrations than systemic TAC it may be an effective delivery system for TAC in the treatment of psoriasis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072063     DOI: 10.1046/j.1365-2133.2002.04800.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

Review 1.  [Topical treatment of psoriasis: a systematic update].

Authors:  R Aschoff; G Wozel; M Meurer
Journal:  Hautarzt       Date:  2003-02-13       Impact factor: 0.751

2.  [New immunosuppressive agents for treating psoriasis].

Authors:  S Ortiz-Urda; K Rappersberger
Journal:  Hautarzt       Date:  2003-02-18       Impact factor: 0.751

Review 3.  [Calcineurin inhibitors for topical therapy in psoriasis].

Authors:  J Wohlrab
Journal:  Hautarzt       Date:  2006-08       Impact factor: 0.751

Review 4.  Immunosuppressive and anti-inflammatory properties of engineered nanomaterials.

Authors:  A N Ilinskaya; M A Dobrovolskaia
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

5.  Suppression of cytokine gene expression and improved therapeutic efficacy of microemulsion-based tacrolimus cream for atopic dermatitis.

Authors:  Manisha S Lalan; Naresh C Laddha; Jigar Lalani; Muhammad J Imran; Rasheedunnisa Begum; Ambikanandan Misra
Journal:  Drug Deliv Transl Res       Date:  2012-04       Impact factor: 4.617

6.  Challenges and Opportunities in Radiation-induced Hemorrhagic Cystitis.

Authors:  Bernadette M M Zwaans; Heinz G Nicolai; Michael B Chancellor; Laura E Lamb
Journal:  Rev Urol       Date:  2016

Review 7.  Nanotechnology in dermatology.

Authors:  João Roberto Antonio; Carlos Roberto Antônio; Izabela Lídia Soares Cardeal; Julia Maria Avelino Ballavenuto; João Rodrigo Oliveira
Journal:  An Bras Dermatol       Date:  2014 Jan-Feb       Impact factor: 1.896

Review 8.  Nonsteroidal Topical Immunomodulators in Allergology and Dermatology.

Authors:  Marina Jovanović; Zoran Golušin
Journal:  Biomed Res Int       Date:  2016-04-06       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.